^
Association details:
Biomarker:MET positive
Cancer:Solid Tumor
Drug:GST-HG16 (c-MET inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Title:

Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy Evaluation of GST-HG161

Excerpt:
...Patients with solid tumors confirmed c-Met positive by testing....
Trial ID:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

First-in-human (FIH) phase I study of GST-HG161, a potent and highly selective c-met inhibitor, in patients with advanced solid tumor. Add to Collection

Published date:
05/28/2020
Excerpt:
...6 patients (CRC 2, Gastric 1, NSCLC 1, HCC 1, Cholangiocarcinoma 1) were enrolled to 3 dose levels (60, 150, and 300 mg). Of these 6 patients, 4 had discontinued GST-HG161 treatment at the data cut-off date of Feb 1, 2020, due to progressive disease (3) and adverse event (1). Two patients at the 300 mg cohort are still on treatment. Overall, 4/6 patients showed no drug related AEs > Grade 1....GST-HG161 has been well tolerated to date in study patients with a manageable safety profile.
DOI:
10.1200/JCO.2020.38.15_suppl.e16126